Patients with newly diagnosed benign prostatic hyperplasia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study aimed to characterize patients with newly diagnosed benign prostatic hyperplasia (BPH) and identify patterns that lead to late diagnosis of the disease. Study design. Simple open retrospective non-comparative study. Material and methods. To determine the frequency of requests for medical care for BPH, the study analyzed medical records of3544 patients who sought outpatient urological care at the municipal polyclinic # 26 in Novosibirsk in 2013. Outpatient medical cards of 165 patients with newly diagnosed BPH were analyzed. Results. Among 3544 patients seen by the urologist of the polyclinic, 960 (27.1%) had BPH. Analysis of medical records of 165 men with newly diagnosed BPH showed that the disease was associated with age. The shortest duration of the disease (0.8+0.5 years) was noted in patients under 50 years old, the longest (4.7±2.1 years) in men over 70 years old. The smallest prostate volume was 32 ml, the largest 150 ml. The mean size of the gland naturally increased with age. The mean PSA level also naturally increased with age: from 1.1+0.8 ng/ml in individuals up to 50 years to 3.0±0.7 ng/ml in patients older than 70 years. The maximum IPSS was in the 61-70 year age group (16.7±5.9 points); the minimum IPSS was in the age group up to 50 years (9.5±3.6 points). The duration of the symptoms directly correlated with the prostate volume. At the prostate volume of 60 ml and more, symptom scores showed a 1.5 fold increase. In married patients, the mean IPSS was 13.8+5.4, while in single men it was 16.3+5.5 (p=0.008). Conclusion. Patients with BPH account for 27.1% of all patients seeking urological care at the polyclinic. In young men, symptom severity is lower than that in senior men. However, the elderly are more concerned about their symptoms, they have worse quality of life, and they seek medical attention earlier. Married patients are more likely to see a urologist with significantly less severe symptoms than single men.

Full Text

Restricted Access

About the authors

I. O Meshkov

Novosibirsk TB Research Institute of Minzdrav of Russia

Email: urotub@yandex.ru
Junior Researcher

E. V Kulchavenya

Novosibirsk TB Research Institute of Minzdrav of Russia; Novosibirsk State Medical University of Minzdrav of Russia

Email: urotub@yandex.ru
Dr.Med.Sci., Prof., Principal Researcher; Prof. at Department of Tuberculosis

S. Yu Shevchenko

Novosibirsk TB Research Institute of Minzdrav of Russia

Email: urotub@yandex.ru
Ph.D., Senior Researcher

A. I Neimark

Altai State Medical University of Minzdrav of Russia

Email: urologagmu@mail.ru
Dr.Med.Sci., Prof., Head of the Department of Urology and Andrology with the Course of Specialized Surgery

References

  1. Zhang B., Wei J., Wu X., Wang L., Huo H., Wang J. Clinical optimal dose of solifenacin succinate for nursing patients after transurethral resection of the prostate during the perioperative period. ExpTherMed. 2018;15(2):1660-1665. doi: 10.3892/etm.2017.5567.
  2. Nunes R., Oliveira R., Carneiro A., Neto A.M., Antunes A.A., Bernardo W.M., Silvinato A., Sarma A.V., Parsons J.K., McVary K., Wei J.T. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know? J. Urol. 2009;182(6 Suppl.):S32-37. Doi: 10.1016/j. juro.2009.07.088.
  3. Гаджиева З.К., Казилов Ю.Б. Новые возможности лечения комбинированных симптомов нижних мочевыводящих путей у пациентов с доброкачественной гиперплазией предстательной железы - предпосылки и преимущества. Урология. 2017;1:95-102
  4. Lepor H. Pathophysiology, Epidemiology, and Natural History of Benign Prostatic Hyperplasia. Rev Urol. 2004; 6(Suppl. 9): S3-S10.
  5. Иващенко В.А., Рогозина А.А. Роль бактериологических и морфологических исследований в диагностике хронического простатита при ДГПЖ. Современные проблемы науки и образования. 2015;4:335
  6. Taoka R., Kakehi Y. The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. Asian J. Urol. 2017;4(3):158-163. doi: 10.1016/j.ajur.2017.02.004.
  7. Кульчавеня Е.В., Брижатюк Е.В., Бреусов А.А. Гиперактивный мочевой пузырь как маска хронического простатита. Урология. 2012;6:43-47
  8. Кульчавеня Е.В., Чередниченко А.Г., Неймарк А.И., Шевченко С.Ю. Частота встречаемости госпитальных уропатогенов и динамика их чувствительности. Урология. 2015;2:13-16
  9. Chute C.G., Panser L.A., Girman C.J., Oesterling J.E., Guess H.A., Jacobsen S.J., Lieber M.M. The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol. 1993;150(1):85-89.
  10. Liu R.F., Fu G., Li J., Yang Y.F., Wang X.G., Bai P.D., Chen Y.D. Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats. ExpTher. Med. 2018;15(3):2703-2710. Doi: 10.3892/ etm.2018.5772.
  11. Liu R.F., Li J., Zhang J., Bai P.D., Yang Y.F., Li W., Wu Z., Zheng J.X. Crosstalk between apoptosis and autophagy in prostate epithelial cells under androgen deprivation. ExpTher Med. 2018;15(3):2263-2268. doi: 10.3892/etm.2018.5726.
  12. Тюзиков И.А., Греков Е.А., Калинченко С.Ю. Особенности клинического течения и морфометрических параметров доброкачественной гиперплазии предстательной железы у мужчин с метаболическим синдромом и андрогенным дефицитом. Урология. 2015;5:47-52
  13. Осадчий А.В., Кульчавеня Е.В., Рейхруд Т.А. и др. Социально-демографическая характеристика больных туберкулезом легких и внелегочных локализаций. Туберкулез и болезни легких. 2015;2:46-49
  14. Кирпатовский В.И., Чочуев О.С., Надточий О.Н., и др. Метаболический синдром: влияние на прогрессирование ДГПЖ, симптомов нижних мочевых путей и эффективность терапии ДГПЖ (обзор литературы). Экспериментальная и клиническая урология. 2017;1:74-83
  15. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36(4):403-15, v. doi: 10.1016/j.ucl.2009.07.003.
  16. Gratzke C., Schlenker B., Weidlich P., Seitz M., Reich O., Stief C.G. Benign prostatic hyperplasia: background and diagnosis. MMW Fortschr Med. 2007;149(33-34):25-28.
  17. Parsons J.K., Sarma A.V., McVary K., Wei J.T. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J. Urol. 2013;189(1 Suppl.):S102-106. Doi: 10.1016/j. juro.2012.11.029. Review.
  18. Jiang Y.H., Wang C.C., Kuo H.C. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. PLoS One. 2018;13(2):e0190704. doi: 10.1371/journal.pone.0190704. eCollection 2018.
  19. Thomas D., Chughtai B., Kaplan S. Commentary on «Solving the benign prostatic hyperplasia puzzle». Asian J. Urol. 2018;5(1):10-11. doi: 10.1016/j.ajur.2016.09.007.
  20. Гланц С. Медико-биологическая статистика. М.: Практика. 1999. 459 с.
  21. Field A., Miles J., Field Z. Discovering statistics using R. Sage publications. 2012.957 p.
  22. Nunes R., Oliveira R., Carneiro A., Neto A.M., Antunes A.A., Bernardo W.M., Silvinato A. Benign prostatic hyperplasia: laser prostatectomy (PVP). Rev Assoc Med Bras (1992). 2017;63(11):929-940. doi: 10.1590/1806-9282.63.11.929.
  23. Xu P., Xu A., Chen B., Zheng S., Xu Y., Li H., Shen H., Liu C. Bipolar transurethral enucleation and resection of the prostate: Whether it is ready to supersede TURP? Asian J. Urol. 2018;5(1):48-54. doi: 10.1016/j. ajur.2017.12.001.
  24. Chung A.S.J., Woo H.H. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J. Urol. 2018;5(1):22-27. Doi: 10.1016/j. ajur.2017.06.001.
  25. Yang P.S., Chen C.L., Hou C.P., Lin Y.H., Tsui K.H. An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin. ClinInterv Aging. 2018;13:235-242. doi: 10.2147/CIA.S152701. eCollection 2018.
  26. Miotta P., Dobruch J., Lipinski M., Drewa T., Kolodziej A., Barcz E., Baranowski W., Rechberger T., Chtosta P.L. Diagnostic and therapeutic recommendations for patients with nocturia.Cent European J. Urol. 2017;70(4):388-393. doi: 10.5173/ceju.2017.1563.
  27. Ng L.G. Botulinum toxin and benign prostatic hyperplasia. Asian J. Urol. 2018;5(1):33-36. doi: 10.1016/j.ajur.2017.11.003.
  28. Kim E.H., Brockman J.A., Andriole G.L. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018;5(1):28-32. doi: 10.1016/j.ajur.2017.11.005.
  29. Jacobsen S.J., Girman C.J., Guess H.A., et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol. 1996;155:595-600.
  30. McConnell J.D., Roehrborn C.G., Bautista O., et al. The long-term effects of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies